An Efficacy and Safety Study of Mitiperstat (AZD4831) (MPO inhibitor) vs placebo in the treatment of moderate to severe COPD. - CRESCENDO

Study identifier:D6582C00001

ClinicalTrials.gov identifier:NCT05492877

EudraCT identifier:2022-002441-18

CTIS identifier:N/A

Recruitment Complete

Official Title

A Phase IIa Randomised, Double Blind, Placebo Controlled, Parallel Arm, Multi-Centre Study to Evaluate the Efficacy and Safety of Mitiperstat (AZD4831), for 12-24 weeks, in Patients with Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)

Medical condition

Chronic obstructive pulmonary disease (COPD)

Phase

Phase 2

Healthy volunteers

No

Study drug

Mitiperstat (AZD4831)

Sex

All

Actual Enrollment

381

Study type

Interventional

Age

40 Years - 80 Years

Date

Study Start Date: 14 Nov 2022
Estimated Primary Completion Date: 16 Aug 2024
Estimated Study Completion Date: 16 Aug 2024

Study design

Allocation: Randomized
Endpoint Classification: -
Intervention Model: Parallel Assignment
Masking: -
Primary Purpose: Treatment

Verification:

Verified 01 Aug 2024 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria